Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi has completed a non-interventional national study titled ‘An Observational National Pediatric Study on Prevalence of Unexplained Splenomegaly.’ The study aimed to assess the prevalence of Gaucher disease in pediatric patients with unexplained enlarged spleens after ruling out common causes. It also sought to describe the rate of identified diseases and characteristics of patients without a final diagnosis.
The study did not involve any interventions, as it was observational in nature. It focused on pediatric patients with unexplained splenomegaly, assessing them through clinical examinations and routine tests.
The study was designed as an observational cohort with a cross-sectional time perspective. This means it observed a group of patients at a single point in time without any interventions.
The study began on April 12, 2021, and was completed by September 22, 2025. These dates are significant as they mark the study’s timeline from initiation to the last update, providing a framework for the data collection period.
This study’s completion could influence Sanofi’s stock performance and investor sentiment positively, as it adds to the company’s research portfolio in rare diseases. In the competitive landscape, this study may position Sanofi as a leader in pediatric rare disease research, potentially affecting its market standing.
The study is completed, with further details available on the ClinicalTrials portal.